Clinical Trial Update: Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients [Phase 2]

View source ↗

Summary

Novartis' Phase 2 trial of the CSF-1R pathway inhibitor BLZ945 in amyotrophic lateral sclerosis was terminated, with trial results posted on 2025-03-19.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• BLZ945

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: TERMINATED | Results posted: 2025-03-19